Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
Excluding items, adjusted earnings for the quarter $1.35 billion or $11.56 per share, compared to $1.18 billion or $10.24 per share in the year-ago quarter.
On average, 23 analysts polled by Thomson Reuters expected the company to report earnings of $10.61 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the quarter grew 12 percent to $3.55 billion from $3.16 billion in the same quarter last year. Analysts were looking for revenues of $3.38 billion for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.